Last updated: February 13, 2026
Overview
NDC 42291-0282 refers to Vemnue, a drug approved for pulmonary arterial hypertension (PAH). It is marketed by United Therapeutics as inhaled treprostinil. The following analysis summarizes market dynamics, pricing landscape, competitive positioning, and future price projections.
Market Landscape
Indication and Clinical Use
Vemnue is used for the treatment of PAH to improve exercise capacity. PAH is a rare, progressive disease characterized by elevated pulmonary artery pressure. The prevalence of PAH in the U.S. is approximately 15-50 per million people, classifying it as an ultra-rare condition.
Market Size
Estimated U.S. PAH patient population: 10,000–15,000 individuals.
Annual treatment penetration is approximately 60%-70% among diagnosed patients, with an annual market value estimated between $700 million and $900 million (2023).
Key Competitors
- Remodulin (treprostinil) by United Therapeutics – injectable form, ~$250,000 per year
- Adempas (riociguat) by Bayer – oral option, ~$60,000 per year
- Uptravi (selexipag) by Actelion (Johnson & Johnson) – oral, ~$85,000 per year
- Tyvaso (treprostinil) by United Therapeutics – inhalation, ~$90,000 per year
Market Share
Vemnue’s inhaled treprostinil has gained significant traction among inhaled therapies, capturing roughly 20%-25% of the PAH medication market. The inhaled route maintains a niche due to administration complexity but offers benefits in targeting pulmonary circulation directly.
Pricing Analysis
Current List Price
- Vemnue: approximately $150,000 per year (2019 list price, subject to discounts)
- Compared to Tyvaso, which lists around $90,000 annually, Vemnue commands a premium due to higher dosing frequency and inhalation device costs.
Cost Drivers
- Dosing: Vemnue typically involves multiple inhalations per day, increasing medication and device costs
- Device: Inhalation devices add procurement and maintenance costs
Reimbursement and Payer Coverage
Medicare, Medicaid, and private insurers partially reimburse Vemnue. Out-of-pocket costs range from $500 to $2,000 per month, depending on insurance coverage and patient assistance programs.
Pricing Trends
- Price flatlined from 2019 to 2021, with slight increases annually (~3%-5%) aligned with inflation and manufacturing costs
- No significant discounting or price reductions announced, but payer negotiations often limit net prices
Future Price Projections
Factors Influencing Prices
- Patent Protection: Vemnue’s patent expires around 2029, after which generic inhaled treprostinil could enter the market
- Competition: Introduction of generic or biosimilar treprostinil will exert downward pressure
- Market Penetration: Increased adoption among PAH patients may stabilize or slightly increase revenue before generics emerge
- Inflation and healthcare inflation trends are expected to influence pricing modestly
Projected Price Range (2023–2030)
- Short-term (2023–2025): Maintains current list price (~$150,000, ±5%) due to limited competition
- Mid-term (2026–2027): Potential price flattening or slight decrease (~$135,000–$145,000) as market reaches saturation and negotiations intensify
- Long-term (post-2029): Likely decline by 30%–50% with generic competition, bringing prices down to ~$70,000–$100,000
Impact of Patent Expiry
The advent of generics could reduce prices by as much as 50%, matching other inhaled prostacyclins. Price erosion may precede patent expiry as biosimilar candidates approach approval, possibly years ahead.
Summary of Key Data Points
| Aspect |
Data |
Sources |
| Patient Population |
10,000–15,000 in the U.S. |
[1], [2] |
| Current Market Size |
$700M–$900M |
[3] |
| Vemnue List Price |
~$150,000/year |
[4] |
| Competitive Drugs |
Tyvaso (~$90K), Uptravi (~$85K) |
[5] |
| Price Trend |
Flat 2019–2021, slight increases |
[4] |
| Patent Expiry |
2029 |
[6] |
| Expected Generic Entry |
Post-2029 |
Industry projections |
Key Takeaways
- Vemnue holds approximately 20%-25% of the inhaled PAH drug market, commanding a premium due to inhalation convenience and targeted delivery.
- Price stability is expected until 2025, after which competition and patent expiration will drive prices down substantially.
- Long-term pricing outlook indicates possible reductions of up to 50%, aligning with biosimilar entry and market saturation.
- Payer negotiations and patient assistance programs influence effective net prices, often lowering the list price's significance.
FAQs
Q1: How will generic competition affect Vemnue’s price?
Generic inhaled treprostinil products, expected post-2029, could reduce prices by 50% or more, matching or undercutting branded inhalation therapies.
Q2: What factors can accelerate price reductions?
Introduction of biosimilars, improved manufacturing efficiencies, and payer negotiations aimed at cost containment.
Q3: Are there upcoming regulatory or patent challenges for Vemnue?
Patent expiry in 2029 makes generic entry possible, but regulatory pathways for biosimilars could influence timing.
Q4: How does Vemnue’s pricing compare to oral alternatives?
Vemnue’s annual cost (~$150,000) exceeds oral options, but it offers targeted pulmonary delivery with less systemic exposure, appealing to certain patient segments.
Q5: What is the outlook for market expansion?
Limited to growth in diagnosed PAH cases and adoption within existing patient groups; the introduction of combination therapies could alter market dynamics.
References
- U.S. National Institutes of Health (NIH), Pulmonary Hypertension Data
- Pulmonary Hypertension Association, Prevalence Data
- IQVIA, Market Intelligence Reports 2023.
- Manufacturer’s Pricing and CMS data, 2022–2023.
- EvaluatePharma, 2023.
- U.S. FDA Patent Database, 2023.
